<DOC>
	<DOCNO>NCT00361920</DOCNO>
	<brief_summary>The hypothesis patient demonstrate steroid resistant asthma show little improvement lung function course oral steroid different cellular response steroid patient steroid sensitive . These altered response reason demonstrate steroid resistance .</brief_summary>
	<brief_title>Cell Biology Steroid Resistant Asthma</brief_title>
	<detailed_description>Current NHLBI guideline persistent asthma management recommend use steroid treatment airway inflammation ( 1,2 ) . However , asthmatic respond steroid ( 3-6 ) . Unfortunately patient subject unwanted side effect ( osteoporosis , cataract , etc ) high dose steroid therapy non-immune tissue remain sensitive steroid . Recent study suggest cost asthma largely attributable uncontrolled disease ( 7 ) . Thus , important understand mechanism ( ) steroid resistance introduce new form therapy treatment difficult control asthmatic . As prelude pharmaceutical study steroid resistant asthma , imperative develop biomarkers robustly identify individual likely poor steroid responder alternative non-steroid anti-inflammatory therapy , Xolair® , introduce early course asthma therapy .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>1 . Will meet American Thoracic Society criterion asthma 2 . Pulmonary function test consistent asthma . This include baseline FEV1 &lt; 80 % predict well 12 % improvement FEV1 follow 4 puff albuterol . 3 . Subjects must 12 65 year old . 1 . Viral infection within four week start date . 2 . Abnormal hepatic function . 3 . History COPD 4 . Pregnancy . 5 . History smoking . 6 . Anemia ( hemoglobin le 12 gm % ) 7 . Concurrent therapy anticonvulsant , erythromycin , rifampin systemic asthma medication include Singular® , Xolair® oral prednisone . 8 . Greater 500 mcg per day inhale corticosteroid 9 . Suspected noncompliance medical care . 10 . Abnormal prednisone pharmacokinetics ( applies phase 2 trial ) 11 . Patients severe medical condition view investigator prohibits participation study ( specify require ) 12 . Use investigational agent last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>steroid resistant asthma</keyword>
</DOC>